Skip to main content
Message Font: Serif | Sans-Serif
No. of Recommendations: 2
I received this from JDRF Today - I'm copying it because I don't see any copyright notice on it, and because it was in an email, there's no web page to which I can link:

At JDRF, we’re all working towards one goal, and we know you are fighting for the same thing - to accelerate research for better treatment options for those living with type 1 diabetes (T1D), and ultimately, for prevention and a cure. Here’s what our researchers are working on:

Children with two or more autoantibodies—the markers of T1D—have a nearly 100 percent risk of developing it—making diagnosis a question of when, not if. We’re working on universal screenings, to get people with antibodies into clinical trials that will evaluate ways to delay the onset of T1D and to identify those at high risk. This could potentially prevent diabetic ketoacidosis (DKA) at diagnosis, a serious, life-threatening condition.

Targeting and ultimately restoring proper immune balance is central to JDRF’s efforts to ultimately cure T1D. Research is finding exciting immunotherapy advances and breakthroughs right now in cancer and other autoimmune diseases—science we can use to advance new therapeutic approaches for T1D.

Beta Cell Regeneration
Restoring and protecting the insulin-producing beta cells could be key to us finding a cure. JDRF spearheaded efforts to advance beta cell regenerating and beta cell survival therapies and these efforts are progressing towards clinical testing. In the next fiscal year, we will focus on clinical testing of repositioned drugs—drugs approved for other diseases—that have the potential to improve beta cell survival and to continue to advance the pipeline of new therapies for survival and regeneration of beta cells, translating scientific discoveries into real-life therapies.

Beta Cell Replacement
There are some amazing advances in the science of beta cell encapsulation. Encapsulation is an advanced form of transplantation in which an implanted protective material surrounds the beta cells, letting insulin out, oxygen and other nutrients in and keeping immune attacks away. We’re exploring new ways to take these therapies to the next level.

Artificial Pancreas
Thanks to JDRF leadership, the first artificial pancreas system gained FDA approval in 2016. But what if an insulin pump, a continuous glucose monitor (CGM) and an algorithm could “talk” to each other, regardless of whether they have the same manufacturer? Just imagine if you could mix and match components together into a safe and effective artificial pancreas system. It’s not that far away. There is already one CGM system—the Dexcom G6—that has been approved under a new FDA pathway that enables such interoperability, and JDRF is working with partners to encourage more in the future.

Glucose/Metabolic Control
Tight control over blood-sugar levels can be a struggle for those with T1D, and we want to make it much easier to manage. How can we improve non-device based therapies (with both insulin and non-insulin drugs) so that they help restore glucose control and reduce complications for those with T1D? JDRF wants to build on the successes of non-insulin therapies that complement insulin. We’re collaborating across our research areas to improve blood-sugar control and the time people stay in a healthy range.

Despite advances in treatments, most people are not meeting their glycemic targets. And even people in good control of their T1D may develop complications with damage often occurring before anyone notices the signs. This can make it a challenge to identify the right people at the right time for treatment or clinical trials. By identifying the markers that are associated with early-stage kidney decline or vision loss, we can change the currently cost-prohibitive and unwieldy drug development processes that are significantly slowing the progress in the field. JDRF is also strategically removing the barrier of T1D exclusion in kidney trials led by the private sector.

You can read JDRF's entire 2017 Annual Report here:

Whose doctor wanted him to invest in a CGM but he just bought into an Accu-Chek Guide to bring blutooth connectivity to his manual glocose monitoring and isn't investing in anything else new a this time...

Ticker Guide for The Walt Disney Company (DIS), SodaStream (SODA), Live Nation (LYV)
Disclaimer: This post is non-professional and should not be construed as direct, individual or accurate advice
Disclosure: May own shares of some, many or all of the companies mentioned in this post (
Fool Code of Conduct:
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.